logo
ServiceNow Stock Up 4% After  Guidance Raise On Agentic AI Growth

ServiceNow Stock Up 4% After Guidance Raise On Agentic AI Growth

Forbes2 days ago
Agentic AI drove up ServiceNow's guidance and the stock rose 4.8% in July 24 morning trade.
SUN VALLEY, IDAHO - JULY 08: ServiceNow CEO Bill McDermott arrives at the Sun Valley Lodge for the ... More Allen & Company Sun Valley Conference on July 8, 2025 in Sun Valley, Idaho. Every year, some of the world's wealthiest and most powerful figures from the media, finance, technology, and political spheres converge at the Sun Valley Resort for the exclusive week-long conference hosted by boutique investment bank Allen & Co. (Photo by) Getty Images Key Facts
ServiceNow's second quarter revenue: $3.22 billion — 23% more than last year and $100 million ahead of the London Stock Exchange Group consensus, noted CNBC .
ServiceNow's Q2 adjusted earnings per share: $4.09 — 63 cents above LSEG view, CNBC reported.
ServiceNow's Q2 continuing remaining performance obligations: $10.92 billion — up 25%, according to CNBC .
2025 subscription revenue guidance: $12.79 billion — $10 million more than analysts' estimate and $150 million more than ServiceNow's previous estimate, noted Yahoo! Finance .
ServiceNow — whose shares are down 5% in 2025 — beat second quarter growth expectations and raised guidance due to 'artificial intelligence adoption,' reported CNBC.
Should you buy the stock? The answer is yes — only if this pattern of beating and raising continues. Despite a potential 2% hit due to tariffs and government budget cuts, according to CNBC , here's why ServiceNow stock could rise: Companies are adopting agentic AI which contributed to ServiceNow's boost to guidance, about which I wrote in my book, Brain Rush .
. ServiceNow is embedding agentic AI into new business processed — notably customer service, field service and supply chain management — which provides new growth opportunities, noted Investor's Business Daily .
My July 24 interviews with ServiceNow President of Global Customer Operations, Paul Fipps, and President and Chief Financial Officer, Gina Mastantuono reveal the company could achieve expectations-beating growth as the company's agentic AI enables customers to boost productivity in employeee and customer service and demand soars in India and the Middle East.
ServiceNow exceeded investor expectations for growth and profitability and raised its guidance for 2025. 'Every business process in every industry is being refactored for agentic AI,' ServiceNow chair and CEO Bill McDermott in a release.
The company also disclosed growth glitches. Seasonality and more customers renewing contracts in the final quarter will reduce third quarter CRPO by 2 percentage points, the company said.
Moreover, U.S. government agency budget changes could affect results 'While federal business is a bit uncertain today versus a year ago, we're navigating it well, and we feel confident that our guidance reflects any potential changes that we're seeing,' Mastantuono told CNBC .
This is a change from ServiceNow's view of the future in April. A few weeks after President Donald Trump launched government job cuts and promulgated tariff confusion, ServiceNow saw opportunity.
As companies aim to "optimize their supply chains amid recent tariff announcements and federal clients aim to boost efficiency amid government spending cuts, the platform is operating in a best-case-scenario environment,' McDermott said according to my April Forbes post. How Agentic Ai Demand Is Boosting Servicenow's Growth
ServiceNow was enjoying growth from AI last April and sees that growth is continuing. "Our AI business quadrupled year over year and our average deal size increased by a third.' Mastantuono told me in April.
ServiceNow remains optimistic about growth due to enterprise AI spending. "We are rocking,' ServiceNow CEO Bill McDermott told Yahoo! Finance. In pursuit of margin-boosting cost savings, ' AI spending will be up significantly into year-end," he added.
ServiceNow says it does a better job of making agentic AI — prompting an AI chatbot to, say, plan, book and pay for a vacation to Paris and letting the AI agent pick the best hotels, restaurants, and visits — payoff.
'We improve productivity in a range of 50% to 85%,' Fipps told me. 'Our AI platform for business transformation completes work in the workflow. We manage the complexity of enterprise architecture — bringing data from enterprise resource planning, customer relationship management, and other systems into the cloud and using NowAssist to deliver intelligent workflow.'
For instance, ServiceNow saves time and reduces the cost of fulfilling employee software purchase requests. One of ServiceNow's largest brand customers receives between 2,000 and 4,000 employee requests for software each month.
'Using our AI agents, the customer matches the software purchase to the individual employee's needs and fulfills the order within two to four hours,' Fipps explained. 'This is a big improvement from a process that formerly took two to four days to complete and over provisioned because it did not know each employee's needs,' he added.
ServiceNow sees big growth opportunities in CRM and in the Indian market. 'Sales order management — front to back end — is a fast growing business,' Fipps said. 'We already get $1.4 billion from our CRM business and after acquiring Logik.AI for configuring, pricing, and quoting we got nine deals in June. It is a huge growth factor,' he concluded.
ServiceNow expects explosive growth over the next three years from India. Between 2024 and 2027, ServiceNow forecasts 115% growth from $130 million in 2024 annual contract value to about $280 million in 2027 ACV, according to a July 24 email from a company spokesperson.
Customers in the Indian banking, manufacturing, and telecommunications industries are 'pulling us in,' said Fipps. 'Our brand is becoming much more relevant across the globe. Customers are realizing the ServiceNow platform can revamp the employee experience and CRM,' he concluded. What Cfo And Analysts Are Saying About Servicenow's Growth
ServiceNow's CFO expressed optimism for the company's performance and prospects. 'Q2 was a spectacular quarter across the board, as we significantly beat the high end of our guidance across all topline and profitability metrics,' Mastantuono said according to a company statement.
'Now Assist continued to surpass net new ACV expectations, fueled by an increase in both deal volume and size quarter‑over‑quarter, putting us firmly on track to hit our $1 billion ACV target by 2026. With a robust pipeline and expanding market opportunities, including strong momentum in CRM, we are well‑positioned for the second half of the year,' she added.
Analysts — with an average price target of $1,096 — see 10% upside in the stock, noted TipRanks . Here are two analysts who share her optimism: "We expect NOW to trade up given the solid Q2 beat against a pretty low bar with investor sentiment extremely cautious on application software and NOW's high Federal exposure," Citi analyst Tyler Radke told Yahoo! Finance .
. "ServiceNow delivered a solid quarter and outlook, surpassing what was a high bar of investor expectations in our view for Q2," said RBC Capital analyst Matthew Hedberg in a report feature by IBD .
ServiceNow's CFO highlighted three significant growth opportunities. 'AI plus data plus workflows is a game changer for the enterprise because it produces real business outcomes at scale,' she told me.
'18 of our top 20 deals came from NowAssist — which includes all our AI stock keeping units. We had 50% growth in deal volume and we won our biggest NowAssist deal — of more than $20 million,' added Mastantuono.
'We had remarkable customer transformations with Starbucks, ExxonMobil, Intuit, and Nvidia — which is using our product to personalize employee support with voice response in seconds. Front office transformation — fully integrated selling, fulfillment and service is a huge total addressable market. So is governance, security and risk management,' she concluded.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs
Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs

Yahoo

time9 minutes ago

  • Yahoo

Elevance Health, Inc. (ELV) Downgrades 2025 Earnings Amid Rising Medical Costs

We recently compiled a list of Elevance Health, Inc. stands third on our list among the most undervalued healthcare stocks. Elevance Health, Inc. (NYSE:ELV) is a major U.S. healthcare company, known for its insurance brands Anthem and WellPoint, and its growing Carelon health services arm. It serves around 45.6 million medical plan members and is recognized for integrating technology and value-based care to improve healthcare delivery. The company is facing increased healthcare utilization and rising medical costs, especially in the ACA and Medicaid segments. This has led to a downgrade in full-year 2025 earnings. A 'market-wide morbidity shift' is evident, with new ACA enrollees using emergency services at nearly double the rate of commercial members, and Medicaid patients showing higher acuity due to redeterminations. Amid these challenges, some investors see Elevance Health, Inc. (NYSE:ELV) as one of the most undervalued stocks in the healthcare sector, given its long-term positioning and strategic adjustments. The company expects a surge in elective procedures by Q4 2025 as members act ahead of expiring tax credits in 2026 that could raise their out-of-pocket costs. To address these pressures, the business is ramping up AI-driven tools for risk detection, care coordination, and operational efficiency. It's also expanding value-based care contracts, particularly in behavioral health and oncology, with over one-third of benefit expenses tied to risk-sharing models. The company is adjusting pricing strategies for ACA plans and advocating for Medicaid access amid potential regulatory changes. A healthcare professional discussing a treatment plan with a patient in an outpatient clinic. Though total membership fell by 212,000 in Q2 due to Medicaid attrition, the Medicare Advantage segment continues to grow. Elevance Health, Inc. (NYSE:ELV) is prioritizing long-term financial stability over aggressive member growth as it navigates rising costs, shifting regulations, and post-pandemic care patterns. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Keybanc Hikes Spotify Technology S.A. (SPOT)'s Price Target To $860, Maintains Overweight Rating
Keybanc Hikes Spotify Technology S.A. (SPOT)'s Price Target To $860, Maintains Overweight Rating

Yahoo

time9 minutes ago

  • Yahoo

Keybanc Hikes Spotify Technology S.A. (SPOT)'s Price Target To $860, Maintains Overweight Rating

Spotify Technology S.A. (NYSE:SPOT) is among the 13 Best Global Stocks to Buy Right Now. On July 11, Keybanc lifted the stock's price target to $860 from $640, while maintaining an Overweight rating for its shares. The adjustment represents significant upside potential, given its share price of $674.46 at the close on July 23. Copyright: dennizn / 123RF Stock Photo The firm said that it expects Spotify Technology S.A. (NYSE:SPOT)'s second-quarter results and guidance for the third quarter to contain some variability related to foreign exchange, seasonal gross margin dynamics, and social charges. The analyst has advised investors to buy any near-term dips and reiterated that its core thesis remains intact. Keybanc believes that music is under-monetized in a price inflationary market with favorable competitive dynamics and several initiatives that support high-teens revenue growth. In other news, Deutsche Bank on Wednesday also raised Spotify Technology S.A. (NYSE:SPOT)'s target price to $775 from $700 and maintained a Buy rating for its shares. The Luxembourg-based company, which provides digital music-streaming services worldwide, has seen impressive returns in 2025, gaining 51% year-to-date. While we acknowledge the potential of SPOT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Best Small Cap Defense Stocks to Buy According to Hedge Funds and 13 Best Booming Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment
Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment

Yahoo

time9 minutes ago

  • Yahoo

Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment

We recently compiled a list of Vertex Pharmaceuticals Incorporated stands second on our list and has recently launched the first non opioid acute pain treatment. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a global biotech firm based in Boston, is known for developing innovative treatments for serious diseases like cystic fibrosis, sickle cell disease, and beta thalassemia. The company is recognized for its strong pipeline targeting unmet medical needs. In July 2025, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) launched JOURNAVX (suzetrigine), a first-in-class, non-opioid treatment for moderate-to-severe acute pain. JOURNAVX, an oral NaV1.8 pain signal inhibitor, was named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc. It represents the first new class of pain medicine in decades and offers a safer alternative to opioids by directly targeting pain pathways without addiction risks. This launch marks a major advancement in pain management, aligning with public health efforts to reduce opioid use. JOURNAVX is especially relevant for acute pain scenarios such as post-surgical recovery and injury care. A closeup of pills in a pharmacy, representing the high quality medications of the company. Beyond acute pain, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) continues to expand its reach. Its next-gen cystic fibrosis therapy, ALYFTREK, received approval from the European Commission in July 2025, strengthening its global leadership in this area. The company is also advancing gene-editing therapies like CASGEVY for sickle cell and beta thalassemia, and is developing treatments for kidney disease, type 1 diabetes, and rare genetic disorders. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store